Gilead manufacturing under investigation by US authorities
pharmafile | June 14, 2011 | News story | Manufacturing and Production |Â Â Department of Justice, Gilead, manufacturing compliance, pharma manufacturingÂ
Gilead Sciences is being investigated by the US authorities over the manufacturing and distribution of some of its products, and is ‘cooperating’ with the inquiry.
On Friday the drugmaker confirmed it had received a subpoena from the US Department of Justice for documents related to the “manufacture, and related quality and distribution practices”, for a number of its top medicines.
The probe is looking at Gilead’s actions in the context of both civil and criminal law, said the firm in a press release.
The request applies to the company’s HIV therapies Atripla (efavirenz/emtricitabine/tenofovir), Emtriva (emtricitabine), Truvada (tenofovir/emtricitabine) and Viread (tenofovir); hepatitis drug Hepsera (adefovir); and pulmonary arterial hypertension drug Letairis (ambrisentan).
The US Attorney’s Office for the Northern District of California is also requesting information on one of Gilead’s investigational drugs, namely its fixed-dose combination of Truvada and Johnson & Johnson’s Edurant (rilpivirine).
At present it is not clear whether the subpoenas relate to an ongoing FDA investigation into Gilead’s manufacturing facility in San Dimas, California.
Last September, Gilead was sent an FDA warning letter detailing a number of problems at the site, including problems with the maintenance of aseptic processing conditions which could lead to a risk of products becoming contaminated.
The agency also cited a lack of effective quality control systems and inadequate environmental monitoring programmes. One of the drugs mentioned in the DoJ probe – Viread – was cited in the warning letter, although most of the citations involved other products such as the injectable antifungal AmBisome (liposomal amphotericin B).
Phil Taylor
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
Gilead shares phase 3 results from HIV prevention trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …
